These big changes will take place in the pharmaceutical industry under the normalization of mining

"Pharmaceutical network industry dynamics" since November 2018, the state launched the "4 plus 7" drug collection pilot work, less than 2 years, has carried out two batches of drug collection work, the current third batch of drug collection has also entered the practical stage.
With the drug collection from the pilot to the national expansion, and then immediately into the normal operation stage, pharmaceutical reform is showing the trend of advancing in many ways, inevitably will have a profound impact on the development of pharmaceutical enterprises and the entire industry, then under these effects of the pharmaceutical industry will happen what big changes? Drug enterprise innovation drug research and development will become more and more intense with volume procurement is essentially a revolution to stimulate innovation.
Although it is more significant to save on health care expenses in the short term or to actually reduce the burden of drug use by the people, in the long run, the policy objective is to promote the high profile of the innovation drug and innovative drug research and development industry chain.
In turn, with the increasing normalization of volume procurement, more and more pharmaceutical companies have realized that the long-term focus on generic drug research and development production will not make money, the layout of innovative drugs will be more substantial development.
At present, the industry generally believes that, with the roll-out of the volume procurement policy, pharmaceutical production enterprises can obtain large-scale orders through a one-time centralized transaction, the sales promotion intensity of the winning varieties will be greatly reduced;
And in a variety of positive factors superimposed, for enterprises to provide research and development innovation of the capital soil environment, domestic pharmaceutical companies want to survive in the market competition and stand firm, will certainly step up the transformation and upgrading, will continue to invest more resources in new drug research and development.
pharmaceutical retail industry has been accelerating for a long time, the hospital market has been the main selling position of prescription drugs.
, with the gradual progress of the volume procurement policy, the unseeded varieties almost lost the country's major public hospital sales market.
in order to regain market share in the past, these varieties have been selling outside the retail market.
data show that in 2019, China's three major terminal drug sales reached 1795.5 billion yuan, an increase of 4.8% year-on-year.
, the share of public hospital terminals, while still large, was 66.6% in 2019, down from 67.4% in 2018, while the market share of retail pharmacies terminals was 23.4% in 2019 and has been growing for many years.
to this, industry experts believe that the hospital as the main channel for prescription drug sales is rapidly weakened, the future drug sales main channel will be transferred from the hospital to professional pharmacies, the layout of the terminal retail market enterprises may usher in more good.
, it is worth noting that in the process of drug transfer to the retail market, how pharmacies and pharmacies can find a symbly win-win relationship is still facing various uncertainties.
for pharmacies, in the short term is expected to enjoy the industry dividends brought about by mining, but in the long term, mining will also promote the concentration of the industry, industrial development will be full of changes.
half of pharmaceutical representatives or eliminated from the impact of the volume procurement policy, pharmaceutical companies are facing huge cost control challenges.
background, whether it is domestic or foreign enterprises, the news of the dissolution of the pharmaceutical delegation team began to become more and more common.
For example, Beijing Jialin Pharmaceuticals announced in late October that it was disbanding its sales team because of the failure of the company's Atovastatin calcium product, Alle, to win the bid during the expansion of the collection, while Sanofi, a multinational pharmaceutical company, also optimized the diversion of Polivi's medical and sales teams.
from the above comprehensive point of view, the good days of pharmaceutical representatives in today's volume procurement normalization has indeed been much worse than before.
Some industry sources have pointed out that the pain of pharmaceutical representatives has only just begun, and that in the next five years or so, half of the medical representatives may be eliminated, especially those who are not professional and cannot really do academic promotion.
the future, medical representatives will gradually return to the original academic promotion of the original intention.